A multinational consortium has produced the first comprehensive oncogenomic map of domestic cats, revealing that key driver mutations—including TP53 and FBXW7—occur in felines at frequencies strikingly similar to those seen in human cancers. The findings position pet cats as natural models for comparative oncology and open new avenues for “One Medicine” approaches to cancer treatment.
A Pan‑Species Cancer Atlas
The study, “The oncogenome of the domestic cat,” appeared online in Science on 19 February 2026 (Vol. 391, Issue 6787, pp. 793‑799; DOI 10.1126/science.ady6651). Researchers from the Wellcome Sanger Institute, Ontario Veterinary College (University of Guelph), University of Bern, and Cornell University analyzed 493 tumor–normal pairs collected from routine veterinary diagnostics across Canada, the United Kingdom, Germany, Austria, and New Zealand.
Targeted next‑generation sequencing focused on the feline orthologs of ≈ 1,000 human cancer‑associated genes (978 genes in the final panel). Thirteen tumor types were represented, with feline mammary carcinoma (MAM) providing the largest cohort. The cats were predominantly domestic shorthairs (73 % of samples) and ranged in age from eight to eleven years at diagnosis.
Driver Genes Shared With Humans
Across all tumor types the consortium identified 31 likely driver genes. Five of these—TP53, PTEN, FBXW7, CTNNB1, and TRAF3—were recurrent in multiple cancers, mirroring the multi‑cancer drivers that dominate human pan‑cancer analyses.
| Gene | Frequency in Feline Tumors | Human Pan‑Cancer Frequency |
|---|---|---|
| TP53 | 33 % | ~34 % |
| PTEN | 20 % | ~25 % |
| FBXW7 | 5–7 % overall; >50 % in mammary carcinoma | <5 % overall; enriched in aggressive breast subtypes |
| CTNNB1 | 4 % | ~7 % |
| TRAF3 | 3 % | ~4 % |
The TP53 mutation rate in cats (33 %) aligns almost exactly with the ~34 % mutation burden reported in human pan‑cancer datasets, underscoring a deep evolutionary conservation of this tumor‑suppressor pathway.
Feline Mammary Carcinoma Mirrors Human Breast Cancer
Mammary carcinoma was the most genetically characterized feline cancer in the cohort. Two driver alterations stood out:
- FBXW7 Mutations: More than 50 % of feline mammary tumors harbored FBXW7 alterations, with some sub‑analyses reporting up to 72 %. In human oncology, FBXW7 mutations are relatively rare overall but are strongly linked to aggressive, poor‑prognosis breast cancers, especially triple‑negative subtypes.
- PIK3CA Hotspot (p.H1047R): Detected in 30 % of feline mammary carcinomas, this exact hotspot drives PI3K‑AKT signaling in human breast cancer and is a validated target for FDA‑approved PI3K inhibitors.
These parallels suggest that feline mammary carcinoma can serve as a natural, out‑bred model for studying high‑risk human breast cancers, particularly those driven by FBXW7 loss.
Actionable Mutations and Early Drug‑Response Experiments
The authors flagged 14 % of all feline tumors as harboring at least one mutation in a set of seven genes with existing targeted therapies: PIK3CA, MAP2K1, KIT, FBXW7, FGFR2, PTEN, and NF1. To explore therapeutic relevance, the team generated three‑dimensional tumoroids from FBXW7‑mutant feline mammary cancers. In vitro, these tumoroids displayed heightened sensitivity to vinca alkaloids—specifically vincristine and vinorelbine—relative to FBXW7‑wild‑type controls. The observation mirrors earlier work in human HAP1 cell lines, where FBXW7 loss sensitized cells to the same agents.
While promising, the authors caution that in vitro sensitivity does not guarantee clinical efficacy. Controlled trials in live feline patients are required before these drugs can be recommended as standard care for FBXW7‑mutant cancers.
The “One Medicine” Rationale
Domestic cats share ≈ 90 % of their protein‑coding genome with humans, a higher similarity than the ~84 % shared with dogs. Moreover, cats live in the same indoor environments as their owners, exposing them to comparable pollutants, tobacco smoke, and synthetic chemicals. This ecological overlap makes cats uniquely suited as sentinel species for environmentally driven mutagenesis.
The open‑access feline oncogenomic reference database released alongside the paper provides a platform for bidirectional data exchange:
- Veterinary Oncology: Clinicians can now match a cat’s tumor mutation profile to human‑targeted agents, potentially expanding treatment options beyond conventional cytotoxic chemotherapy.
- Human Oncology: Researchers can study naturally occurring, aggressive tumor subtypes—such as FBXW7‑mutant breast cancer—in a large, genetically diverse population that is otherwise difficult to capture in human clinical trials.
Limitations and Unresolved Questions
- Genome Annotation Gaps: The feline reference genome remains less thoroughly annotated than its human and canine counterparts. Consequently, some cat‑specific driver mutations—especially those lacking direct human orthologs—may have been missed.
- Targeted Panel Constraints: By focusing on ~1,000 human‑derived genes, the study may have overlooked novel feline oncogenes. Whole‑exome sequencing was performed on only 18 mammary tumors, limiting broader discovery.
- Preclinical versus Clinical Evidence: The vinca‑alkaloid sensitivity of FBXW7‑mutant tumoroids is an early, preclinical observation. No in vivo trials have yet validated these findings in pet cats.
- Environmental Causality: Although the authors highlight shared indoor exposures as a plausible source of overlapping mutational signatures, the study does not establish direct causal links between specific household chemicals and particular feline mutations.
Implications for Future Research
The comparative oncogenomic map establishes domestic cats as a high‑value translational model for studying driver mutations that are central to human cancers. By integrating feline mutation data with human clinical trial databases, researchers could prioritize trials of PI3K inhibitors, MAPK pathway agents, or vinca alkaloids in both species. Moreover, expanding the dataset to include whole‑genome sequencing and larger numbers of rare tumor types will likely uncover additional cat‑specific drivers and refine the “One Medicine” pipeline.
The study’s open‑access database and its demonstration of actionable mutations in pet cats herald a new era in which veterinary and human oncology move from parallel tracks to a shared, data‑driven pathway.